Answers are grounded in this paper and cite their sources.
This single-centre retrospective study evaluates IDFS and safety outcomes in early-stage HER2-positive breast cancer, suggesting the potential of T-DM1 biosimilars in routine practice.
In the KATHERINE trial, adjuvant trastuzumab emtansine (T-DM1) significantly improved invasive disease-free survival (IDFS) in patients with residual HER2-positive breast cancer following neoadjuvant therapy. Real-world data on T-DM1 biosimilars in the post-neoadjuvant setting remain limited, particularly in low- and middle-income countries. This study evaluated IDFS and safety outcomes of a T-DM1 biosimilar in routine Indian clinical practice.
No takes yet. Share an insight, caveat, or question.
K.B. Patel (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: